Amphetamines are sometimes prescribed in Canada for attention deficit hyperactivity disorder (ADHD) and narcolepsy. One of the most commonly used amphetamines is D-methamphetamine, which is twice as strong as its predecessor, the d1-met, and easier to produce. It is important to note that the production, distribution, and sale of methamphetamine are restricted or illegal in many jurisdictions. To better understand the prevalence of methamphetamine use in British Columbia, a study was conducted to analyze the epidemiology of crystalline methamphetamine use among people who use substances in the area. The results showed that its use was strongly associated with the use of opioids, cannabis, and alcohol.
Additionally, two-thirds of those who had used treatment with opioid agonists in the past three days also reported using crystalline methamphetamine. The study also found that 77% and 67% of participants were detected with methamphetamine in their urine (true prevalence) and 69.0% reported using crystalline methamphetamine in the past three days (apparent prevalence). This indicates that self-reported use of crystalline methamphetamine is a valid measure for determining its prevalence. Given the high prevalence of co-use of crystalline methamphetamine and opioids, it is important to further develop and evaluate therapeutic options for stimulant use disorder and opioid use disorder in the context of multiple substance use. This will help to reduce the harmful consequences that may arise from using both substances.